PT - JOURNAL ARTICLE AU - Gao, Zeyu AU - Mao, Anyu AU - Dong, Yuxing AU - Wu, Jialun AU - Liu, Jiashuai AU - Wang, ChunBao AU - He, Kai AU - Gong, Tieliang AU - Li, Chen AU - Crispin-Ortuzar, Mireia TI - Accurate spatial quantification in computational pathology with multiple instance learning AID - 10.1101/2024.04.25.24306364 DP - 2024 Jan 01 TA - medRxiv PG - 2024.04.25.24306364 4099 - http://medrxiv.org/content/early/2024/04/26/2024.04.25.24306364.short 4100 - http://medrxiv.org/content/early/2024/04/26/2024.04.25.24306364.full AB - Spatial quantification is a critical step in most computational pathology tasks, from guiding pathologists to areas of clinical interest to discovering tissue phenotypes behind novel biomarkers. To circumvent the need for manual annotations, modern computational pathology methods have favoured multiple-instance learning approaches that can accurately predict whole-slide image labels, albeit at the expense of losing their spatial awareness. We prove mathematically that a model using instance-level aggregation could achieve superior spatial quantification without compromising on whole-slide image prediction performance. We then introduce a superpatch-based measurable multiple instance learning method, SMMILe, and evaluate it across 6 cancer types, 3 highly diverse classification tasks, and 8 datasets involving 3,850 whole-slide images. We benchmark SMMILe against 9 existing methods, and show that in all cases SMMILe matches or exceeds state-of-the-art whole-slide image classification performance while simultaneously achieving outstanding spatial quantification.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge funding and support from Cancer Research UK and the Cancer Research UK Cambridge Centre [CTRQQR-2021-100012], The Mark Foundation for Cancer Research [RG95043], GE HealthCare, and the CRUK National Cancer Imaging Translational Accelerator (NCITA) [A27066]. Additional support was also provided by the National Institute of Health Research (NIHR) Cambridge Biomedical Research Centre [NIHR203312] and EPSRC Tier-2 capital grant [EP/P020259/1]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee of the First Affiliated Hospital of Xian Jiaotong University gave ethical approval (KYLLSL2021-420, KYLLSL2022-333) for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors